In The News Posted August 24, 2021 Share Posted August 24, 2021 LOS ANGELES, Aug. 24, 2021 /PRNewswire/ -- Athos Therapeutics, Inc., a late preclinical stage biotechnology company pioneering the development of first-in-class precision therapeutics for patients with immune-mediated diseases, announced today a comprehensive Master Research Agreement for...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.